New hope for breast cancer patients with brain tumors: targeted drug combo shows promise
NCT ID NCT04965064
First seen Dec 24, 2025 · Last updated May 02, 2026 · Updated 13 times
Summary
This study tests a combination of two drugs, neratinib and capecitabine, in people with a type of breast cancer that has spread to the brain. The cancer is HER2-negative by standard tests but shows abnormal HER2 activity on a special test. The goal is to see if this treatment can help control the disease and improve survival. About 22 adults with this condition will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Rochester
RECRUITINGRochester, New York, 14642, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.